RS67523B1 - Postupak za dijagnostikovanje i lečenje parcijalne lipodistrofije - Google Patents

Postupak za dijagnostikovanje i lečenje parcijalne lipodistrofije

Info

Publication number
RS67523B1
RS67523B1 RS20251266A RSP20251266A RS67523B1 RS 67523 B1 RS67523 B1 RS 67523B1 RS 20251266 A RS20251266 A RS 20251266A RS P20251266 A RSP20251266 A RS P20251266A RS 67523 B1 RS67523 B1 RS 67523B1
Authority
RS
Serbia
Prior art keywords
variable region
chain variable
amino acid
seq
acid sequence
Prior art date
Application number
RS20251266A
Other languages
English (en)
Serbian (sr)
Inventor
Wenjun Zheng
Charles Harris
Bret Musser
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of RS67523B1 publication Critical patent/RS67523B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4872—Body fat
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/482—Diagnostic techniques involving multiple energy imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dentistry (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Evolutionary Computation (AREA)
RS20251266A 2021-02-22 2022-02-22 Postupak za dijagnostikovanje i lečenje parcijalne lipodistrofije RS67523B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152100P 2021-02-22 2021-02-22
EP22708698.0A EP4294257B1 (en) 2021-02-22 2022-02-22 Method for diagnosing and treating partial lipodystrophy
PCT/US2022/017222 WO2022178382A1 (en) 2021-02-22 2022-02-22 Method for diagnosing and treating partial lipodystrophy

Publications (1)

Publication Number Publication Date
RS67523B1 true RS67523B1 (sr) 2026-01-30

Family

ID=80683255

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20251266A RS67523B1 (sr) 2021-02-22 2022-02-22 Postupak za dijagnostikovanje i lečenje parcijalne lipodistrofije

Country Status (14)

Country Link
US (1) US20240153638A1 (https=)
EP (1) EP4294257B1 (https=)
JP (1) JP2024512255A (https=)
DK (1) DK4294257T3 (https=)
ES (1) ES3055018T3 (https=)
FI (1) FI4294257T3 (https=)
HR (1) HRP20251599T1 (https=)
LT (1) LT4294257T (https=)
PL (1) PL4294257T3 (https=)
PT (1) PT4294257T (https=)
RS (1) RS67523B1 (https=)
SI (1) SI4294257T1 (https=)
SM (1) SMT202500444T1 (https=)
WO (1) WO2022178382A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
PT3773713T (pt) * 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia

Also Published As

Publication number Publication date
WO2022178382A1 (en) 2022-08-25
SI4294257T1 (sl) 2026-01-30
JP2024512255A (ja) 2024-03-19
US20240153638A1 (en) 2024-05-09
HRP20251599T1 (hr) 2026-01-30
DK4294257T3 (da) 2025-12-08
SMT202500444T1 (it) 2026-01-12
PL4294257T3 (pl) 2026-02-09
EP4294257A1 (en) 2023-12-27
FI4294257T3 (fi) 2025-12-19
LT4294257T (lt) 2025-12-29
PT4294257T (pt) 2025-11-28
EP4294257B1 (en) 2025-11-05
ES3055018T3 (en) 2026-02-09

Similar Documents

Publication Publication Date Title
Cobos et al. Dermatomyositis: An Update on Diagnosis and Treatment: GA Cobos et al.
Kwak et al. Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia
RS67523B1 (sr) Postupak za dijagnostikovanje i lečenje parcijalne lipodistrofije
Schmidt et al. Pemphigoid diseases
EP2500730B1 (en) Soluble urokinase plasminogen activator receptor (suPAR) as diagnostic marker for low-grade inflammation
Orteu et al. Scleroderma mimics–clinical features and management
US20150110741A1 (en) Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
KR20190012199A (ko) 난치성 전신 중증 근무력증의 치료를 위한 방법
KR20210039402A (ko) 알츠하이머병의 치료 및 예방 방법
Junyent et al. Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score
US20220340668A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
Frohman et al. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations
de Moreuil et al. Long-term recurrence risk after a first venous thromboembolism in men and women under 50 years old: a French prospective cohort
Takahashi et al. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
HK40105291A (en) Method for diagnosing and treating partial lipodystrophy
HK40105291B (en) Method for diagnosing and treating partial lipodystrophy
CN120641439A (zh) 用于治疗或预防甲状腺素转运蛋白介导的淀粉样变性的方法
Metin et al. The impact of vitamin D deficiency and autoimmunity on chronic spontaneous urticaria severity
Van De Veire et al. Diabetes and impaired fasting glucose as predictors of morbidity and mortality in male coronary artery disease patients with reduced left ventricular function
CN106198953A (zh) 白介素‑33在制备诊断肺源性急性肺损伤试剂盒中的用途
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
Can Evaluation of Patients with Guillain-Barré Syndrome After Covid-19 Infection
May et al. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications
Loser et al. Characteristics and outcome of chronic inflammatory demyelinating polyradiculoneuropathy patients according to their diagnostic certainty based on the 2021 EAN/PNS criteria